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Despite recent advances in multimodal therapy, bladder cancer still ranks ninth in worldwide cancer incidence. New molecules
whichmight improve early diagnosis and therapeutic efficiency for tumors of such high epidemiological impact therefore have very
high priority. In the present study, the tetrabranched neurotensin peptide NT4 was conjugated with functional units for cancer-cell
imaging or therapy and was tested on bladder cancer cell lines and specimens from bladder cancer surgical resections, in order to
evaluate its potential for targeted personalized therapy of bladder cancer. Fluorophore-conjugated NT4 distinguished healthy and
cancer tissueswith good statistical significance (𝑃 < 0.05). NT4 conjugated tomethotrexate or gemcitabinewas cytotoxic for human
bladder cancer cell lines at micromolar concentrations. Their selectivity for bladder cancer tissue and capacity to carry tracers or
drugs make NT4 peptides candidate tumor targeting agents for tracing cancer cells and for personalized therapy of human bladder
cancer.
1. Introduction
Specific targeting of tumor-associated antigens, selectively
expressed or overexpressed by tumor cells, are the goal of
modern cancer therapy aimed at increasing drug efficiency
and decreasing its nonspecific toxicity. To achieve selec-
tive tumor treatment, diagnosis should provide information
about expression of tumor-specific antigens that might be
targeted by specific drugs or drug-carriers.
The use of peptides as tumor-targeting agents was envis-
aged years ago when it was found that receptors for different
endogenous regulatory peptides are overexpressed in several
primary and metastatic human tumors and can be used as
tumor antigens [1, 2].
The bottleneck for development of peptides as drugs has
always been their extremely short half-life, due to physio-
logical degradation by peptidases and proteases. Different
chemical modifications, which can be introduced to obtain
stabilized analogues, may profoundly change peptide affinity
or specificity. Coupling of peptides to effector units for tumor
imaging or therapy may also interfere with peptide biological
activity.
Peptides synthesized in an oligobranched form [3] retain
peptide biological activity or even increase it through multi-
valent binding [4] and are very resistant to proteolysis, pro-
viding much higher in vivo activity than the corresponding
monomeric peptides [5–7].
We studied the use of oligobranched peptides containing
the sequence of the human regulatory peptide neurotensin
(NT4) as specific tumor targeting agents that can selectively
and specifically deliver effector units for cell imaging or
killing to tumor cells [6, 8]. We proved that NT4 can effi-
ciently and selectively deliver functional units or liposomes
[9] for cell imaging or therapy to different human cancer cells.
Using NT4 conjugated to methotrexate or 5FdU, we obtained
60% and 50% reductions, respectively, in adenocarcinoma
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In the present study, NT4 was tested in vitro on HT-1376
andT24 bladder cancer (BC) cell lines (in vitroPhase I) and ex
vivo on human BC samples from patients undergoing radical
cystectomy or endoscopic transurethral resection of the
bladder and the healthy tissue counterpart of the same patient
(ex vivo Phase I) to evaluate its ability to recognize specific
membrane receptors and to be internalized. Drug-conjugated
NT4 and the corresponding free drug were compared in vitro
(in vitro Phase II) to evaluate the capacity of NT4 to enhance
the cytotoxic effect of the drug. An upcoming ex vivo Phase II
on BC patients will be carried out in order to test tracers and
chemotherapeutics conjugated with NT4.
2. Materials and Methods
2.1. Peptide Synthesis. Peptides were synthesized on an auto-
mated multiple synthesizer (MultiSynTech, Germany) by
standard Fmoc chemistry. Protected L-amino acids and
Tentagel-resin were purchased from Iris Biotech, Germany,
DIPEA (N,N-diisopropylethylamine) from Merck and
HBTU (O-benzotriazole-N,N,N󸀠,N󸀠-tetramethyl-uronium-
hexafluoro-phosphate) fromMultiSynTech.
Tetrabranched peptides were built using two consecu-
tive Fmoc-Lys(Fmoc)-OH coupling steps. NT4-biotin was
synthesized on Tentagel resin with Fmoc-Lys(biotin)-OH as
first coupling step and Fmoc-PEG
12
-OH as second; Fmoc-
Lys(Fmoc)-OH was then used to build the tetrameric core.
Pyro-glu-O-pentachlorophenylester (Bachem, Switzerland)
was used for the last coupling step, since pyro-glu is the N-
terminal acid of the neurotensin sequence.
Peptides conjugated with chemotherapy drugs were syn-
thesized using Fmoc-Lys(Dde)-OH as the first amino acid on
Tentagel resin; then the second amino acid was Fmoc-𝛽Ala-
OH. Two coupling steps with Fmoc-Lys(Fmoc)-OH were
used to build the core. Pyro-glu-O-pentachlorophenylester
(Bachem, Switzerland) for NT(1–13) was the N-terminal acid.
Once the sequence was completed, the Dde protective group
was removed using 2% hydrazine in DMF (v/v) on resin and
the free amino group was coupled with Fmoc-PEG
12
-OH.
The Fmoc group was then removed to enable coupling with
Boc-methotrexate or gemcitabine-ester. Gemcitabine-ester
was prepared as already reported, with slight modification
[6]. Unrelated analogues were synthesized similarly and the
N-terminus was acetylated before the conjugation steps.
Once the solid phase synthesis was completed, the peptides
were cleaved from the resin, deprotected, and lyophilized.
HPLC purification was performed on a C18 Jupiter
Phenomenex column. Water (A) containing 0.1% TFA and
methanol (B) were used as eluents. Gradients of B in 30min
were run at flow rates of 0.8mL/min and4mL/min for analyt-
ical and preparatory procedures, respectively. All compounds
were also characterized on an Ettan MALDI-TOFmass spec-
trometer (Amersham Biosciences, Buckinghamshire, UK).
2.2. Bladder Cancer Cell Culture. T24 urinary bladder transi-
tional cell carcinoma andHT-1376 urinary bladder carcinoma
cells were obtained from Istituto Zooprofilattico Sperimen-
tale (Brescia). T24 and HT-1376 cells were grown in their
recommended media, McCoy’s 5A and Eagle’s minimum
essential medium (MEM), respectively, supplemented with
10% fetal bovine serum, 200𝜇g/mL glutamine, 100𝜇g/mL
streptomycin, and 60 𝜇g/mL penicillin in a humidified atmo-
sphere with 5% CO
2
at 37∘C.
2.3. In Vitro Phase I: Peptide Binding and Internalization. The
binding and internalization of tracing unit-conjugated NT4
was tested in HT-1376 and T24 cell lines. 3 × 104 cells/well
were seeded on 24-well plates, grown for 24 hours, blocked
for 30min at 37∘C with 3% BSA in TBS, and then incubated
with NT4 peptide (5 𝜇M in TBS-0.3% BSA). Experiments
were performed with peptide conjugated to biotin and then
incubated with 0.5𝜇g/mL SA-Cy3. After 30 minutes of
incubation at room temperature, the cells were washed with
0.3% BSA in TBS and grown in medium for 1, 2, or 4 h at
37∘C to allow peptide internalization. Subsequently, the cells
were fixed with TBS 4% formalin; then plasma membranes
were stained with Lectin-FITC (0.5 𝜇g/mL in TBS-0.3% BSA)
incubated for 15min at room temperature and nuclei were
stained with DAPI (0.5 𝜇g/mL in TBS-0.3% BSA). Each step
was followed by three washes in TBS. Peptide binding and
internalization were analysed by confocal laser microscope
(LeicaTCS SP5)with 550
𝜆ex and 570–590𝜆em, 380𝜆ex and 450–
470
𝜆em, and 488𝜆ex and 530–550𝜆em for Cy3, DAPI, and FITC,
respectively.
2.4. In Vitro Phase II: Cytotoxicity of Drug-Conjugated Pep-
tides. T24 and HT-1376 cells were plated at a density of
5 × 103 per well in 96-well microplates. Different con-
centrations of free or NT4-conjugated drugs, from 0.15 to
30 𝜇M, were added 24 h after plating. Cells incubated with
methotrexate-conjugated peptidewere grownwithout chang-
ing the medium for 6 days. Cells treated with gemcitabine-
conjugated peptide were washed after 2 h incubation and
then were left 6 days at 37∘C with the same medium.
Growth inhibition was assessed by 3-(4,5-dimethylthiazol-
2-yl)-2,5-diphenyltetrazolium bromide (MTT). Cytotoxicity
of drug-conjugated NT4 was compared with that of the
corresponding free drugs and of an unrelated tetrabranched
peptide, identically conjugated to the same drug.
2.5. Ex Vivo Phase I: Human Tissue Collection and Analysis.
Samples of BC (K) were collected from patients undergoing
either transurethral resection of bladder or radical cystec-
tomy at Urology Clinic I, University Hospital of Florence.
Samples of morphologically normal bladder mucosa (H)
were collected from the same patient. The presence of tumor
and healthy tissue was checked by standard staining proce-
dures. Tissue samples from BC and healthy mucosa were
stained with NT4-biotin, followed by streptavidin-FITC.
Samples were embedded in Tissue-Tek and stored in liquid
nitrogen. 10 𝜇m thick sections, obtained with a Leica CM1850
UV, were dried at 37∘C for 30min, fixed with 4% formalin for
15min at room temperature, and incubated in glycine 0.1M
for 12 hours at 4∘C. Blocking with FBS for 30min at 37∘C was
followed by incubation for 30min at room temperature with
NT4-Biotin (1 𝜇g/mL) and SA-FITC (0.5 𝜇g/mL). Each step
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Figure 1: Binding and internalization (0 h, 1 h, 2 h, and 4 h) of NT4 (red) on HT-1376 human bladder cell carcinoma (a) and T24 urinary
bladder transitional cell carcinoma (b). Nuclei are stained with DAPI (blue) and plasma membrane is stained with Lectin-FITC (green).
was followed by washing with TBS. Controls were performed
using an unrelated biotin-conjugated tetrabranched peptide.
Peptide binding was analysed by confocal laser microscope
(Leica TCS-SP5) with 488
𝜆ex and 530–550𝜆em. All images
were processed using ImageJ software (NIH). All patients
were given a written informed consent module to read and
sign before surgery, including detailed explanations of tissue
sample collection and management of sensitive data. This
study was carried out with approval of the Ethics Com-
mittee, Careggi, Florence (Protocol number 2009/0018748,
27.04.2009).
2.6. Statistical Analysis. The electronic data from image
analysis was expressed as pixel distribution in the green color
range of the RGB scale. Data was further analysed using
Graph Pad Prism 5.03 software. Descriptive statistics (mean±
standard deviation and range) were used to summarize
variables, while the nonparametric Wilcoxon rank test for
paired samples was used to compare fluorescence signals
in healthy and tumor tissue. For cytotoxicity determination,
EC
50
values were calculated by nonlinear regression analysis.
Values from untreated controls gave 100% cell viability. The
level of significance was set at 𝑃 < 0.05 for two-sided testing.
3. Results
3.1. In Vitro Phase I: Peptide Binding and Internalization.
Binding and internalization of NT4 was tested in the HT-
1376 cell line, which was chosen as representative of human
bladder epithelial cell carcinoma, and in the T24 cell line,
representative of transitional cell carcinoma. Cells were
treated with 5𝜇M NT4-biotin and then with streptavidin-
Cy3 that provides a red signal. Peptide binding onmembrane
receptors was observed after 30 minutes of incubation at
room temperature. Cells were then washed and incubated
for a further 1, 2, or 4 h to follow peptide internalization. At
time 0, NT4 red signal was localized on cell membranes. At
the following incubation times, NT4 was clearly visualized
intracellularly, both in HT-1376 and T24 cells (Figure 1).
3.2. In Vitro Phase II: Cytotoxicity of NT4 Conjugated to
Chemotherapeutics. Cytotoxicity of NT4 conjugated with
methotrexate (MTX) or gemcitabine (GEM) was tested in
vitro in HT-1376 and T24 bladder carcinoma cell lines. Drug-
armed NT4 was tested for stability and ability to release the
drug when incubated with cells. On the basis of the different
links and bonds between NT4 peptides and the drugs, we
classified drug-armed peptides as slow-releasing or fast-
releasing adducts. Slow-releasing drug-armed NT4 released
less than 10%of the conjugated drug in 24 hours, whereas fast-
releasing adducts can release 50% of the conjugated drug in 2
hours of incubation [8]. MTX-conjugated NT4 was a slow-
releasing adduct, whereas GEM-conjugated NT4 was fast-
releasing. Figure 2 shows the cytotoxicity of drug-conjugated
NT4 compared with that of the corresponding free drugs and
an unrelated tetrabranched peptide, identically conjugated to
the same drug.
MTX was strongly active on HT-1376 and even more on
T24.The conjugated peptide was less active than the free drug
(EC
50
1.4 ⋅ 10−7 and 4.0 ⋅ 10−7 in HT-1376 and T24, resp.)





























































































Figure 2: Cytotoxicity of NT4 peptide conjugated with methotrexate (MTX), or gemcitabine (GEM) in T24 (a) and HT-1376 (b) cell lines.
Cytotoxicity of drug-conjugated NT4 (NT4-GEM or NT4-MTX) was compared with that of the corresponding free drugs (GEM or MTX)
and an unrelated tetrabranched peptide (U4-GEM or U4-MTX), identically conjugated to the same drug.
but gained strong selectivity as shown by the curve obtained
with the MTX-conjugated unrelated peptide U4-MTX. This
result confirms that conjugation of MTX with NT4 turns
the chemotherapeutic into an inactive prodrug, where MTX
cannot exert its cytotoxic activity in the absence of peptide-
dependent cell internalization [5, 6]. GEM and NT4-GEM
were inactive on HT-1376 cells. NT4-GEM was as active as
free GEM on T24.
3.3. Ex Vivo Phase I: Human Tissue Collection and Analysis.
Samples from 16 patients who had undergone surgical resec-
tion of bladder cancer or endoscopic biopsy were obtained
from the Urology Unit of Careggi Regional and University
Hospital, Florence. Samples ofmorphologically normal tissue
(healthy) from the same patients were collected from normal
bladder mucosa. The presence of tumor and healthy tissue
was checked by standard staining procedures (Figure 3).
Bladder cancer and healthy tissue samples were stained
with NT4-biotin, followed by streptavidin-FITC (Figure 4).
A significant difference between tumor and healthy tissue
signals was observed in all samples. RGB type images were
collected and analysed to quantify fluorescent staining in
each healthy and tumor tissue. RGB images were expressed
as pixel distributions in the green color range using ImageJ
software (NIH), translating the immunofluorescence signals
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Figure 4: Confocal microscopy of human bladder cancer biopsies. Tumor tissue (K) and the corresponding healthy tissue (H) were stained
with NT4 peptide conjugated with biotin, followed by streptavidin-FITC (green). Nuclei are stained with DAPI (blue).
into numbers representing the median value of green stain-
ing. Fourteen out of the 16 bladder cancers were diagnosed
histologically as urothelial carcinoma (Table 1).
No correlation was found in the comparison between
tumor staging (TNM in Table 1) and K/H value. This means
that NT peptide can be used for early diagnosis and treatment
of bladder cancer because the difference between tumor and
healthy tissues in the early stages of the disease is substantial.
Statistical analysis to evaluate any difference in peptide
binding between healthy and tumor tissues showed a signifi-
cant difference in fluorescent signal between the two groups
(Figure 5). Indeed the signal from tumor samples was at least
two-fold that, from the respective healthy tissue, is also visible
from the K/H ratios shown in Table 1.
4. Discussion
Due to its high reoperation rate, bladder cancer has the
highest lifetime treatment costs per patient of all cancers [10].
Bladder cancer is the fourth most common cancer among
men and it is the ninth leading cause of death from cancer
[11]. Recurrence and progression rate after endoscopic and
intravesical treatments are 50–70% and 10–30%, respectively
[12]. This leads to further endoscopic transurethral bladder
resection or major surgery such as radical cystectomy.
Beside the intrinsic aggressiveness of bladder cancer,
other critical aspects of this unsatisfactory outcome are
related to suboptimal diagnosis of carcinoma in situ and flat
tumors, which are not visualized in up to 39% of cases by
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Table 1: Clinical features of bladder tumor samples.
Entry Gender Age Type 𝐾/𝐻 TNM
1 M 72 Urothelial carcinoma 2,2 T2
2 M 82 Small cell carcinoma 7,5 T3b Nx Mx
3 M 66 Urothelial carcinoma 7,6 T3a N0 Mx
4 M 72 Urothelial carcinoma 2,8 T3a N0 Mx
5 M 55 Urothelial carcinoma 1,7 T2a N0 Mx
6 M 85 Urothelial carcinoma 2,3 Tx N1 Mx
7 F 80 Urothelial carcinoma 2,7 T4 Nx Mx
8 M 83 Urothelial carcinoma 1,1 T2b N0 Mx
9 M 83 Urothelial carcinoma 1,1 T2a N0 Mx
10 M 71 Urothelial carcinoma 2 T2
11 M 60 In situ carcinoma 4,4 Tis Nx Mx
12 M 81 Urothelial carcinoma 3,9 Ta Nx Mx
13 M 52 Urothelial carcinoma 2,2 Ta Nx Mx
14 M 72 Urothelial carcinoma 2,7 T1
15 M 73 Urothelial carcinoma 2,7 T2b N0 Mx
16 M 73 Urothelial carcinoma 1,2 T2b N0 Mx
𝐾/𝐻 ratio was calculated on the median of𝐾 (tumor) and𝐻 (healthy) RGB values.


















n P < 0.0001
Figure 5:Comparison ofmeanfluorescence values in normal (mean
H, light gray) and cancer (mean K, gray) tissue from human bladder
specimens. The box represents the interquartile range (25–75th
percentile) and the horizontal line in the box is the median value.
Bottom and top bars of the whiskers indicate the minimum and
maximum values, respectively.
common white light cystoscopy and to the limited efficacy
of the current adjuvant treatments [13]. A recent study based
on a long-term follow-up showed that 30% of patients treated
with bacillus Calmette-Gue´rin had progression of the disease
2–6weeks after transurethral resection [14, 15].More effective
adjuvant treatments are thus mandatory to reduce bladder
cancer recurrence and progression.
The use of endogenous peptides for targeted personalized
therapy has been envisaged as a promising approach in
innovative selective cancer targeting [16]. Overexpression of
tumor-associated antigens in several tumors can be capi-
talized by targeting these antigens with specific molecules,
which might be selective for cancer cells.
Branched neurotensin sequences can confer the stability
required for development of molecules with clinical pur-
poses.Moreover, the three-lysine core offers additional chem-
ical groups which can be used for conjugation of functional
units outside the biologically active sequence. It has been
demonstrated that NT4 branched neurotensin peptides are
much more selective than native monomeric neurotensin in
binding to different human cancer cells and tissues and that
conjugation to different functional units does not affect its
binding properties [5, 6].
In this study we tested T24 and HT-1376 cell lines,
as representative of bladder cancer, for their binding and
internalization of NT4 peptide. In both cases we observed
complete peptide internalization within one hour. The same
cell lines were also tested with NT4 peptide conjugated with
chemotherapy drugs. When conjugated with NT4 peptide,
methotrexate was strongly active against HT-1376 and even
more so for T24.
As reported in previous studies [6, 8], although con-
jugation of a cytotoxic drug with NT4 may lead to a
reduction in cytotoxicity in vitro, there may be a gain in
selectivity and specificity which cannot be obtained with
an unrelated branched peptide. This ultimately gives the
NT4-conjugated drug higher in vivo activity than the free
drug, as we already demonstrated by treating mice carrying
xenografts of human colon adenocarcinoma cell lines with
NT4-conjugated methotrexate and free methotrexate [5].
NT4-conjugated gemcitabine was as active against T24 cells
as the free drug.
The ex vivo experiment on samples from patients under-
going surgery for bladder cancer showed thatNT4 conjugated
with a fluorescent probe discriminated between healthy and
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tumor tissues. Statistical analysis confirmed a substantial
difference in fluorescence between healthy and tumor tissues
with a heterogeneous response among patients. This finding
substantiates evidence that the phenotype of a particular
disease may vary between patients, so that treatments should
be tailored on an individual basis. The results indicate that
NT4 conjugated with fluorescent probes can be used in
fluorescence cystoscopy, offering an improvement in the
detection of flat neoplastic lesions, such as carcinoma in
situ.The samemolecule conjugatedwith chemotherapy drugs
can be used in intravesical treatments to prevent disease
recurrence and possible progression.
5. Conclusion
The modularity of the tetrabranched peptide could be a
powerful feature because it allows the molecule to be armed
with a therapeutic drug or with a probe for diagnosis [17].
The possibility of using the same molecule, firstly conjugated
with fluorophores, to “label” cancer cells during endoscopy
and then conjugated with chemotherapeutic drugs to treat
tumors by bladder instillation, has important implications
for a personalized approach to bladder cancer. The results
indicate that NT4 peptides are a promising new selective
tumor-targeting theranostic for human bladder cancer and
may enable personalized oncology in which cancer diagnosis
and therapy are obtained bymeans of the samemolecule, with
nomodification in target binding but by simply “exchanging”
the functional units.
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